These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15172119)

  • 1. Effect of LY293111 in combination with gemcitabine in colonic cancer.
    Hennig R; Ding XZ; Tong WG; Witt RC; Jovanovic BD; Adrian TE
    Cancer Lett; 2004 Jul; 210(1):41-6. PubMed ID: 15172119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
    Tong WG; Ding XZ; Hennig R; Witt RC; Standop J; Pour PM; Adrian TE
    Clin Cancer Res; 2002 Oct; 8(10):3232-42. PubMed ID: 12374694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.
    Hennig R; Ventura J; Segersvard R; Ward E; Ding XZ; Rao SM; Jovanovic BD; Iwamura T; Talamonti MS; Bell RH; Adrian TE
    Neoplasia; 2005 Apr; 7(4):417-25. PubMed ID: 15967119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel anti-pancreatic cancer agent, LY293111.
    Ding XZ; Talamonti MS; Bell RH; Adrian TE
    Anticancer Drugs; 2005 Jun; 16(5):467-73. PubMed ID: 15846111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.
    Jänne PA; Paz-Ares L; Oh Y; Eschbach C; Hirsh V; Enas N; Brail L; von Pawel J
    J Thorac Oncol; 2014 Jan; 9(1):126-31. PubMed ID: 24346102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model.
    Melstrom LG; Bentrem DJ; Salabat MR; Kennedy TJ; Ding XZ; Strouch M; Rao SM; Witt RC; Ternent CA; Talamonti MS; Bell RH; Adrian TA
    Clin Cancer Res; 2008 Oct; 14(20):6525-30. PubMed ID: 18927292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
    Jackson WT; Froelich LL; Boyd RJ; Schrementi JP; Saussy DL; Schultz RM; Sawyer JS; Sofia MJ; Herron DK; Goodson T; Snyder DW; Pechous PA; Spaethe SM; Roman CR; Fleisch JH
    J Pharmacol Exp Ther; 1999 Jan; 288(1):286-94. PubMed ID: 9862783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist.
    Marder P; Sawyer JS; Froelich LL; Mann LL; Spaethe SM
    Biochem Pharmacol; 1995 May; 49(11):1683-90. PubMed ID: 7786309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models.
    Yao B; He QM; Tian L; Xiao F; Jiang Y; Zhang R; Li G; Zhang L; Hou JM; Wang L; Cheng XC; Wen YJ; Kan B; Li J; Zhao X; Hu B; Zhou Q; Zhang L; Wei YQ
    Hum Gene Ther; 2005 Sep; 16(9):1075-86. PubMed ID: 16149906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
    Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
    Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas.
    Saif MW; Oettle H; Vervenne WL; Thomas JP; Spitzer G; Visseren-Grul C; Enas N; Richards DA
    Cancer J; 2009; 15(4):339-43. PubMed ID: 19672152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.
    Baetz T; Eisenhauer E; Siu L; MacLean M; Doppler K; Walsh W; Fisher B; Khan AZ; de Alwis DP; Weitzman A; Brail LH; Moore M
    Invest New Drugs; 2007 Jun; 25(3):217-25. PubMed ID: 17146732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
    Ye YN; Wu WK; Shin VY; Bruce IC; Wong BC; Cho CH
    Carcinogenesis; 2005 Apr; 26(4):827-34. PubMed ID: 15637091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical combination chemotherapy of nedaplatin with gemcitabine against gemcitabine-refractory human lung cancer.
    Takeda Y; Wada T; Nishitani Y; Matsumoto M; Hojo K; Maekawa R; Yoshioka T
    Cancer Lett; 2002 Aug; 182(1):61-8. PubMed ID: 12175524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antitumor activity of combination treatment combining gemcitabine with topotecin against human lung cancer xenografted in nude mice].
    Fujita F; Koike M; Fujita M
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):577-84. PubMed ID: 11977542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
    Hong SK; Yang SY; Yin SH; Yang KX
    Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
    Jin K; Lan H; Xie B; He K; Xu Z; Li G; Han N; Teng L; Cao F
    Cancer Biol Ther; 2012 Jul; 13(9):737-44. PubMed ID: 22617773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.